Literature DB >> 10419542

The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.

M Feelisch1, P Kotsonis, J Siebe, B Clement, H H Schmidt.   

Abstract

Soluble guanylyl cyclase (sGC) is an important effector for nitric oxide (NO). It acts by increasing intracellular cyclic GMP (cGMP) levels to mediate numerous biological functions. Recently, 1H-[1,2, 4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ) was identified as a novel and selective inhibitor of this enzyme. Therefore, ODQ may represent an important pharmacological tool for differentiating cGMP-mediated from cGMP-independent effects of NO. In the present study, we examined the inhibitory action of ODQ both functionally and biochemically. In phenylephrine-preconstricted, endothelium-intact, isolated aortic rings from the rat, ODQ, in a concentration-dependent manner, increased contractile tone and inhibited relaxations to authentic NO with maximal effects at 3 microM. Pretreatment of vascular rings with ODQ induced a parallel, 2-log-order shift to the right of the concentration-response curves (CRCs) to histamine, ATP, NO, the NO-donors S-nitrosoglutathione, S-nitroso-N-acetyl-D,L-penicillamine, and spermine NONOate [N-[4-[1-(3-amino propyl)-2-hydroxy-2-nitroso hydrazino]butyl]-1, 3-propane diamine], and the direct sGC-stimulant [3-(5'-hydroxymethyl-2'furyl)-1-benzyl indazole] YC-1 but did not affect relaxations induced by papaverine and atriopeptin II. Moreover, the rightward shift of the CRCs to Angeli's salt, peroxynitrite, and linsidomine was similar to that of NO. These results suggested that ODQ is specific for sGC. Furthermore, they indicate that NO can cause vasorelaxation independent of cGMP. Three interesting exceptions were observed to the otherwise rather uniform inhibitory effect of ODQ: the responses to acetylcholine, glycerol trinitrate, and sodium nitroprusside. The latter two agents are known to require metabolic activation, possibly by cytochrome P-450-type proteins. The 3- to 5-log-order rightward shift of their CRCs suggests that, in addition to sGC, ODQ may interfere with heme proteins involved in the bioactivation of these NO donors and the mechanism of vasorelaxation mediated by acetylcholine. In support of this notion, ODQ inhibited hepatic microsomal NO production from both glycerol trinitrate and sodium nitroprusside as well as NO synthase activity in aortic homogenates. The latter effect seemed to require biotransformation of ODQ. Collectively, these data reveal that ODQ interferes with various heme protein-dependent processes in vascular and hepatic tissue and lacks specificity for sGC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419542     DOI: 10.1124/mol.56.2.243

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  45 in total

1.  Effects of nitric oxide donors on cardiac contractility in wild-type and myoglobin-deficient mice.

Authors:  J W Wegener; A Gödecke; J Schrader; H Nawrath
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 2.  NO and the vasculature: where does it come from and what does it do?

Authors:  Karen L Andrews; Chris R Triggle; Anthie Ellis
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

3.  Postsynaptic production of nitric oxide implicated in long-term depression at the mature amphibian (Bufo marinus) neuromuscular junction.

Authors:  Sarah J Etherington; Alan W Everett
Journal:  J Physiol       Date:  2004-07-08       Impact factor: 5.182

Review 4.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

5.  Lack of effect of ODQ does not exclude cGMP signalling via NO-sensitive guanylyl cyclase.

Authors:  Barbara Lies; Dieter Groneberg; Stepan Gambaryan; Andreas Friebe
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

6.  Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies.

Authors:  Johannes-Peter Stasch; Cristina Alonso-Alija; Heiner Apeler; Klaus Dembowsky; Achim Feurer; Torsten Minuth; Elisabeth Perzborn; Matthias Schramm; Alexander Straub
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

7.  A photosensitive vascular smooth muscle store of nitric oxide in mouse aorta: no dependence on expression of endothelial nitric oxide synthase.

Authors:  Karen L Andrews; John J McGuire; Chris R Triggle
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  S-nitrosocaptopril: in vitro characterization of pulmonary vascular effects in rats.

Authors:  Debbie Y Y Tsui; Agatha Gambino; Janet C Wanstall
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

9.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013

10.  The role of valvular endothelial cell paracrine signaling and matrix elasticity on valvular interstitial cell activation.

Authors:  Sarah T Gould; Emily E Matherly; Jennifer N Smith; Donald D Heistad; Kristi S Anseth
Journal:  Biomaterials       Date:  2014-01-24       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.